Sucralfate is the trade name and its generic name is Avatropexpa, which is generally not to be taken for long periods of time, and can usually only be taken orally for 5 consecutive days. Avatriptopa, a thrombopoietin receptor agonist, promotes platelet production and is indicated for adult patients with chronic liver disease-related thrombocytopenia who are undergoing elective diagnostic procedures or surgery. It is usually started 10 to 13 days prior to an elective invasive test or procedure and is given once daily, with each dose based on platelet counts, for 5 consecutive days of oral administration. Avatriptopa may be associated with thrombosis and thromboembolic complications in patients with chronic liver disease, and patients with chronic liver disease should not take Avatriptopa to restore platelet counts. Treatment of platelet counts with avatriptopa is dose- and exposure-dependent. An increase in platelet counts is observed within 3 to 5 days after treatment initiation, with a peak after 10 to 13 days, followed by a gradual decrease in platelet counts. Adverse reactions to Avatropexpa include fever, abdominal pain, nausea, headache, fatigue, and peripheral edema are common. In addition, the use of this product in pregnant women may cause harm to the fetus. The use of this product Avatropexpa should be used strictly according to the doctor’s instructions, and patients should not use the drug on their own. To avoid adverse consequences.